MAPK14 and early-onset autosomal dominant Alzheimer disease: As such, the results suggest that targeting MAPK14 activity may be a means to ameliorate the defect in autophagic-lysosomal protein degradation that has otherwise been demonstrated in Alzheimer disease (Fig. 1).